10-Q: Xeris Biopharma Reports Second Quarter 2024 Results, Revenue Growth Driven by Recorlev

Xeris Biopharma's Q2 2024 results show a 26.5% increase in total revenue compared to Q2 2023, driven primarily by strong growth in Recorlev sales.

Summary

• Xeris Biopharma reported a net loss of $15 million for the second quarter of 2024, compared to a net loss of $19.8 million for the same period in 2023.
• Total revenue for Q2 2024 was $48.1 million, a 26.5% increase from $38 million in Q2 2023.
• Product revenue increased by 26.1% to $46.5 million, with Gvoke revenue up 28.2%, Keveyis down 6.8%, and Recorlev up 86.1%.
• For the first six months of 2024, the net loss was $34 million, compared to $36.7 million for the same period in 2023.
• Total revenue for the first six months of 2024 was $88.7 million, a 24.6% increase from $71.2 million in the first six months of 2023.
• The company's cash and cash equivalents were $57.6 million as of June 30, 2024, down from $67.4 million at the end of 2023.
• The company believes its current cash resources are sufficient to sustain operations for at least the next 12 months.
• The company has an accumulated deficit of $651 million as of June 30, 2024.

Sentiment

Score: 7

Explanation: The document shows positive revenue growth, particularly in Recorlev, and a decrease in net loss, which are positive indicators. However, the company still has a significant accumulated deficit and relies on future financing, which introduces some uncertainty. The sentiment is therefore moderately positive.

Positives

• The company experienced significant revenue growth, particularly with Recorlev, indicating strong market demand for its products.
• The net loss decreased compared to the same period last year, suggesting improved financial performance.
• The company successfully refinanced its debt, securing additional capital.
• The company has a strong patent portfolio, providing long-term protection for its products and technologies.
• The company believes its current cash resources are sufficient to sustain operations for at least the next 12 months.

Negatives

• The company continues to operate at a net loss, with an accumulated deficit of $651 million.
• Keveyis revenue decreased by 6.8% in Q2 2024, indicating a potential challenge in this product's market performance.
• Cash and cash equivalents decreased from $67.4 million at the end of 2023 to $57.6 million as of June 30, 2024.
• The company is dependent on a small number of customers for a large portion of its revenue.

Risks

• The company may need to raise additional capital in the future, which could result in dilution to stockholders.
• The company's ability to access capital could be adversely impacted by market volatility and economic conditions.
• The company faces risks related to the successful commercialization and market acceptance of its products.
• The company is subject to ongoing regulatory requirements and may face difficulties in complying with these regulations.
• The company is dependent on key personnel and may face challenges in attracting and retaining qualified employees.
• The company is exposed to interest rate risk on its debt.

Future Outlook

The company expects to continue to incur net losses for at least the next 12 months. The company's ability to fund its operations will depend on the amount and timing of cash received from product revenue and potential future financings.

Management Comments

• The company is focused on building an innovative, self-sustaining, growth-oriented biopharmaceutical company.
• The company's goal is to improve patients' lives by developing and commercializing clinically meaningful products.
• The company is focused on executing against the opportunities made possible by Gvoke, Recorlev, and Keveyis to maintain growth and enable financial self-sufficiency.
• The company is pursuing formulation and development partnerships to enhance the drug delivery and clinical profile of other companies' proprietary drugs and biologics.

Industry Context

The company operates in the competitive biopharmaceutical industry, focusing on treatments for endocrine and metabolic disorders. The growth in Recorlev sales suggests a positive reception in the market for treatments of Cushing's syndrome. The company's proprietary formulation technologies provide a competitive advantage in developing new products and partnerships.

Comparison to Industry Standards

• Xeris's revenue growth of 26.5% in Q2 2024 is strong compared to the average growth rate of many established pharmaceutical companies, but is not unusual for a growth-stage biopharma company.
• The company's focus on rare diseases with products like Recorlev and Keveyis is similar to other specialty pharmaceutical companies such as Horizon Therapeutics and Alexion Pharmaceuticals.
• The company's reliance on a small number of customers is a common risk for smaller biopharma companies, similar to companies like Amarin Corporation before their product gained wider adoption.
• The company's debt refinancing is a common strategy for biopharma companies to manage their capital structure, similar to companies like BioMarin Pharmaceutical.
• The company's R&D spending is typical for a company in its stage of development, with a focus on clinical trials and regulatory filings, similar to companies like Incyte Corporation.

Stakeholder Impact

• Shareholders may be encouraged by the revenue growth and reduced losses, but may be concerned about the need for future financing.
• Employees may be positively impacted by the company's growth and potential for future success.
• Customers may benefit from the company's continued development and commercialization of new treatments.
• Suppliers may see increased business opportunities as the company expands its operations.
• Creditors may be reassured by the company's debt refinancing and improved financial performance.

Next Steps

• The company will continue its marketing and selling efforts related to commercialization of Gvoke, Recorlev and Keveyis.
• The company will continue its research and development efforts, particularly with XP-8121.
• The company will continue to pursue formulation and development partnerships.
• The company expects an FDA End-of-Phase 2 interaction for XP-8121 by year-end.

Key Dates

Keywords

Xeris Biopharma, Gvoke, Recorlev, Keveyis, revenue, net loss, biopharmaceutical, hypoglycemia, Cushing's syndrome, Primary Periodic Paralysis, debt refinancing, patents